Join to View Full Profile
125 Paterson St# ClinicalNew Brunswick, NJ 08901
Phone+1 732-235-7112
Fax+1 732-235-7114
Dr. Fujita is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 2005 - 2008- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2000
Certifications & Licensure
NJ State Medical License 2005 - 2027
NY State Medical License 2004 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 26 citationsNight vision restored in days after decades of congenital blindness.Samuel G Jacobson, Artur V Cideciyan, Allen C Ho, Alejandro J Roman, Vivian Wu
Iscience. 2022-10-21 - 47 citationsPost-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extensionRenato Mantegazza, Gil I. Wolfe, Srikanth Muppidi, Heinz Wiendl, Kenji P. Fujita
Neurology. 2021-01-26 - 19 citationsResponse to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard Nowak, Heinz Wiendl
Therapeutic Advances in Neurological Disorders. 2020-05-06
Press Mentions
Gene Therapy Restores Vision in First-Ever Trial for Rare, Inherited Blindness Finds Lancet StudySeptember 6th, 2024- Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)April 25th, 2023
- Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society MeetingFebruary 8th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
